Join to View Full Profile
909 Fulton St SEMinneapolis, MN 55455
Phone+1 612-273-8383
Fax+1 612-624-1443
Dr. Potter is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. David Potter is an oncologist based in Minneapolis, MN, specializing in breast cancer. He completed his medical education at Johns Hopkins University School of Medicine, followed by a residency in Internal Medicine at Stanford and fellowships in Hematology and Medical Oncology at Brigham and Women's Hospital, Massachusetts General Hospital, Dana-Farber Cancer Institute, and Tufts Medical Center. He has publications focused on topics such as endothelial dysfunction in breast cancer survivors and the impact of body mass index on chemotherapy response. Dr. Potter has conducted clinical trials, including studying the effects of Ritonavir in women undergoing breast cancer surgery, and has received the CMS Meaningful Use Stage 1 Certification.
Education & Training
Tufts Medical CenterFellowship, Hematology and Medical Oncology, 1992 - 1993
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1989 - 1992
Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1986 - 1988
Johns Hopkins University School of MedicineClass of 1982
Certifications & Licensure
CA State Medical License 1988 - Present
MN State Medical License 2006 - 2027
IN State Medical License 2000 - 2007
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Ritonavir and Its Effects on Biomarkers in Women Undergoing Surgery for Newly Diagnosed Breast Cancer Start of enrollment: 2010 May 26
Publications & Presentations
PubMed
- 1 citationsThe partnership between statisticians and the Institutional Animal Care and Use Committee (IACUC).David Potter, Thomas Bradstreet, Davit Sargsyan, Xiao Tan, Vinicius Bonato
Pharmaceutical Statistics. 2024-06-11 - 2 citationsEndothelial dysfunction in breast cancer survivors on aromatase inhibitors: changes over time.Adnan Shaaban, Ashley Petersen, Heather Beckwith, Natalia Florea, David A Potter
Cardio-Oncology. 2024-05-01 - 3 citationsImpact of body mass index on pathological response after neoadjuvant chemotherapy: results from the I-SPY 2 trial.Haiyun Wang, Douglas Yee, David Potter, Patricia Jewett, Christina Yau
Breast Cancer Research and Treatment. 2024-04-01
Grant Support
- Potentiation of immune checkpoint blockade by inhibition of epoxyeicosatrienoic acid driven tumor respirationDOD2019–2022
- Epoxygenase Mechanisms Of Breast Cancer ProgressionNational Cancer Institute2007–2008
- Epoxygenease Mechanisms Of Breast Cancer ProgressionNational Cancer Institute2006
- Epoxygenase Mechanisms Of Breast Cancer ProgressionNational Cancer Institute2005
- Functional Analysis Of Transcription Factors In HIV-1National Cancer Institute1993–1996
Research History
- Associate ProfessorRoles of Cytochrome P450 Arachidonic Acid Oxidases in Breast Cancer Progression
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
